166 related articles for article (PubMed ID: 37383290)
1. Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya.
Mugo NR; Mudhune V; Heffron R; Thomas KK; McLellan-Lemal E; Njoroge B; Peacock S; O'Connor SM; Nyagol B; Ouma E; Ridzon R; Wiener J; Isoherranen N; Erikson DW; Ouattara LA; Yousefieh N; Jacot TA; Haaland RE; Morrison SA; Haugen HS; Thurman AR; Allen SA; Baeten JM; Samandari T; Doncel GF
Front Reprod Health; 2023; 5():1118030. PubMed ID: 37383290
[TBL] [Abstract][Full Text] [Related]
2. Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.
Thurman AR; Schwartz JL; Brache V; Clark MR; McCormick T; Chandra N; Marzinke MA; Stanczyk FZ; Dezzutti CS; Hillier SL; Herold BC; Fichorova R; Asin SN; Rollenhagen C; Weiner D; Kiser P; Doncel GF
PLoS One; 2018; 13(6):e0199778. PubMed ID: 29953547
[TBL] [Abstract][Full Text] [Related]
3. Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.
Thurman AR; Brache V; Cochon L; Ouattara LA; Chandra N; Jacot T; Yousefieh N; Clark MR; Peet M; Hanif H; Schwartz JL; Ju S; Marzinke MA; Erikson DW; Parikh U; Herold BC; Fichorova RN; Tolley E; Doncel GF
PLoS One; 2022; 17(10):e0275794. PubMed ID: 36215267
[TBL] [Abstract][Full Text] [Related]
4. Genital microbiota of women using a 90 day tenofovir or tenofovir and levonorgestrel intravaginal ring in a placebo controlled randomized safety trial in Kenya.
Dabee S; Mugo N; Mudhune V; McLellan-Lemal E; Peacock S; O'Connor S; Njoroge B; Nyagol B; Thurman AR; Ouma E; Ridzon R; Wiener J; Haugen HS; Gasper M; Feng C; Allen SA; Doncel GF; Jaspan HB; Heffron R;
Sci Rep; 2022 Jul; 12(1):12040. PubMed ID: 35835755
[TBL] [Abstract][Full Text] [Related]
5. Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring.
Thurman AR; Ravel J; Gajer P; Marzinke MA; Ouattara LA; Jacot T; Peet MM; Clark MR; Doncel GF
Front Cell Infect Microbiol; 2022; 12():799501. PubMed ID: 35350436
[TBL] [Abstract][Full Text] [Related]
6. Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
Thurman AR; Schwartz JL; Ravel J; Gajer P; Marzinke MA; Yousefieh N; Anderson SM; Doncel GF
PLoS One; 2019; 14(5):e0217229. PubMed ID: 31107913
[TBL] [Abstract][Full Text] [Related]
7. Genital Mucosal Drug Concentrations and anti-HIV Activity in Tenofovir-Based PrEP Products: Intravaginal Ring vs. Oral Administration.
Ouattara LA; Thurman AR; Jacot TA; Cottrell M; Sykes C; Blake K; Fang X; Ju S; Vann NC; Schwartz J; Doncel GF
J Acquir Immune Defic Syndr; 2022 Jan; 89(1):87-97. PubMed ID: 34878438
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC
AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514
[TBL] [Abstract][Full Text] [Related]
9. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
10. A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir.
Thurman AR; Ouattara LA; Yousefieh N; Anderson PL; Bushman LR; Fang X; Hanif H; Clark M; Singh O; Doncel GF
Front Cell Infect Microbiol; 2023; 13():1130101. PubMed ID: 37153145
[TBL] [Abstract][Full Text] [Related]
11. A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex Vivo.
Villegas G; Calenda G; Ugaonkar S; Zhang S; Kizima L; Mizenina O; Gettie A; Blanchard J; Cooney ML; Robbiani M; Fernández-Romero JA; Zydowsky TM; Teleshova N
PLoS One; 2016; 11(7):e0159332. PubMed ID: 27428377
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial.
Schultze-Mosgau MH; Waellnitz K; Nave R; Klein S; Kraetzschmar J; Rautenberg T; Schmitz H; Rohde B
Hum Reprod; 2016 Aug; 31(8):1713-22. PubMed ID: 27390369
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States.
Liu AY; Gundacker H; Richardson B; Chen BA; Hoesley C; van der Straten A; Brown A; Beamer M; Robinson J; Jacobson CE; Scheckter R; Bunge K; Schwartz J; Thurman A; Piper JM; Marzinke MA;
J Int AIDS Soc; 2024 Mar; 27(3):e26223. PubMed ID: 38444118
[TBL] [Abstract][Full Text] [Related]
14. Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model.
Smith JM; Moss JA; Srinivasan P; Butkyavichene I; Gunawardana M; Fanter R; Miller CS; Sanchez D; Yang F; Ellis S; Zhang J; Marzinke MA; Hendrix CW; Kapoor A; Baum MM
PLoS One; 2017; 12(10):e0185946. PubMed ID: 28982161
[TBL] [Abstract][Full Text] [Related]
15. An intravaginal ring that releases three antiviral agents and a contraceptive blocks SHIV-RT infection, reduces HSV-2 shedding, and suppresses hormonal cycling in rhesus macaques.
Derby N; Aravantinou M; Kenney J; Ugaonkar SR; Wesenberg A; Wilk J; Kizima L; Rodriguez A; Zhang S; Mizenina O; Levendosky K; Cooney ML; Seidor S; Gettie A; Grasperge B; Blanchard J; Piatak M; Lifson JD; Fernández-Romero J; Zydowsky TM; Robbiani M
Drug Deliv Transl Res; 2017 Dec; 7(6):840-858. PubMed ID: 28600625
[TBL] [Abstract][Full Text] [Related]
16. Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques.
Moss JA; Malone AM; Smith TJ; Butkyavichene I; Cortez C; Gilman J; Kennedy S; Kopin E; Nguyen C; Sinha P; Hendry RM; Guenthner P; Holder A; Martin A; McNicholl J; Mitchell J; Pau CP; Srinivasan P; Smith JM; Baum MM
Antimicrob Agents Chemother; 2012 Nov; 56(11):5952-60. PubMed ID: 22964245
[TBL] [Abstract][Full Text] [Related]
17. A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.
Johnson TJ; Clark MR; Albright TH; Nebeker JS; Tuitupou AL; Clark JT; Fabian J; McCabe RT; Chandra N; Doncel GF; Friend DR; Kiser PF
Antimicrob Agents Chemother; 2012 Dec; 56(12):6272-83. PubMed ID: 23006751
[TBL] [Abstract][Full Text] [Related]
18. FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir.
Bunge KE; Dezzutti CS; Hendrix CW; Marzinke MA; Spiegel HML; Moncla BJ; Schwartz JL; Meyn LA; Richardson-Harman N; Rohan LC; Hillier SL
J Int AIDS Soc; 2018 Aug; 21(8):e25156. PubMed ID: 30101439
[TBL] [Abstract][Full Text] [Related]
19. Pearl Index study with levonorgestrel-releasing intravaginal rings: using pharmacokinetic results to investigate treatment compliance as a potential contributor for contraceptive failure.
Nave R; Höchel J; Mellinger U; Kohnke A; Elliesen J; Schmitz H
Hum Reprod; 2020 Nov; 35(11):2515-2523. PubMed ID: 32914172
[TBL] [Abstract][Full Text] [Related]
20. Multipurpose prevention technologies: products in development.
Friend DR; Clark JT; Kiser PF; Clark MR
Antiviral Res; 2013 Dec; 100 Suppl():S39-47. PubMed ID: 24188708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
